Interchangeability without switching studies: FDA explains why a new Lucentis biosimilar may be a game-changer
Of the nearly 40 biosimilars approved to date by the FDA, only three have won the coveted interchangeability designation so far, meaning that like small …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
